Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice GuidelineJulie R. Brahmer, John A. Thompson, Christina Lacchetti et al.|Journal of Clinical Oncology|2018Cited by 3.7k
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T ConsortiumLoretta J. Nastoupil, Frederick L. Locke, Patrick M. Reagan et al.|Journal of Clinical Oncology|2020Cited by 782
Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomasQing Deng, Michael R. Green, Luis Fayad et al.|Nature Medicine|2020Cited by 593
Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline UpdateRandy Taplitz, Christopher R. Flowers, Erin B. Kennedy et al.|Journal of Clinical Oncology|2018Cited by 574
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trialNathan Fowler, Catherine Thiéblemont, Michael Dickinson et al.|Nature Medicine|2021Cited by 523